secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001576885-25-000044
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen 2024 net loss $102.3M; cash $231.5M; ALTITUDE-AD enrollment complete
---------------------------------------------------------------------------

- Net loss $102.3M vs $52.4M in 2023; R&D spend $93.8M (up 122%) driven by ALTITUDE-AD trial.
- Cash, equivalents and marketable securities $231.5M, down from $306.1M; runway into H1 2027.
- Phase 2 ALTITUDE-AD enrolled 542 early AD patients; topline results expected late 2026.
- Phase 1 subcutaneous sabirnetug showed mild injection-site reactions; supports further SC development.
- JPAD published Phase 1 INTERCEPT-AD results; sabirnetug well-tolerated with dose-dependent target engagement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000157688525000044/0001576885-25-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000157688525000044/abos-20250327.htm
  HTML page:      https://secwatch.observer/filing/0001576885-25-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer